- Previous Close
0.0000 - Open
0.0094 - Bid 0.0085 x --
- Ask 0.0141 x --
- Day's Range
0.0094 - 0.0094 - 52 Week Range
0.0090 - 0.0900 - Volume
70,000 - Avg. Volume
3,077 - Market Cap (intraday)
13.442M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jun 25, 2025 - Jun 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
www.synairgen.comRecent News: SYGGF
View MorePerformance Overview: SYGGF
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYGGF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYGGF
View MoreValuation Measures
Market Cap
13.55M
Enterprise Value
2.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-42.87M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
8.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--